AAV Capsid Peptide Engineering for Muscle-Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV vectors lack desired tropism and specificity to common therapeutic targets such as muscles, leading to issues like liver toxicity and limited efficacy in gene therapy for muscular disorders.
Innovation Solution
Modified AAV capsid proteins with targeting peptides in variable region VIII and peptide segments in variable region I, optimizing amino acid modifications to enhance muscle tropism and reduce liver tropism, thereby improving gene delivery to muscle tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If natural AAV serotypes are used for gene delivery, then broad tissue tropism is achieved, but specificity to therapeutic targets such as muscles is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific peptide sequences at defined locations within the AAV capsid structure (variable regions I and VIII). These localized peptide modifications confer muscle-specific binding properties to otherwise non-specific AAV serotypes, enabling targeted delivery without altering the overall capsid architecture or requiring complete redesign of the vector system.
2Productivity
If high doses of rAAVs are administered to achieve therapeutic effect, then gene delivery potency is improved, but systemic toxicity increases
Solution Approach 1:
The patent extracts the liver-tropism property from the AAV vector by engineering capsid variants with modified variable regions that specifically exclude hepatocyte binding. This removal of harmful liver targeting capability reduces systemic toxicity and off-target effects, allowing higher therapeutic doses to be administered safely while maintaining muscle-specific gene delivery efficacy.
3Object-affected harmful factors
If local administration of rAAVs is used to improve targeting, then liver tropism is reduced, but delivery efficiency to target tissue decreases
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid sequences in capsid variable regions I and VIII to optimize muscle cell binding affinity. These sequential parameter optimizations (testing multiple peptide variants) enable the vector to maintain high delivery efficiency to muscle tissue while simultaneously reducing liver tropism, resolving the trade-off between safety and efficacy.
Data Source
AI summary
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR, VIII) and/or a peptide segment in variable region I (VR I). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.